Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimum Serum IGF-I Range in Acromegaly Patients Treated With Pegvisomant
2007-003741-33Phase 4Completed
- Sponsor
- Barts Health NHS Trust
- Start
- Nov 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegvisomant in acromegaly, sponsored by Barts Health NHS Trust. Primary endpoint: Achievement and maintenance of subnormal serum IGF-I. Started Nov 2007; status: completed.
02
Drugs
pegvisomant
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2007-003741-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003741-33.